Curis Inc.

Company Overview

Business Model: CURIS, INC. is a biotechnology company primarily focused on the discovery and development of innovative small molecule drug candidates for the treatment of human cancers. Its core value proposition centers on emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). Historically, revenue generation included license fees, research and development payments, and royalties from strategic collaborations. Following the sale of its interest in Erivedge in November 2025, the company's revenue generation is now primarily dependent on future financing and the successful development and commercialization of emavusertib.

Market Position: Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary central nervous system lymphoma (PCNSL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). It also received Orphan Drug Designation from the European Commission for the treatment of PCNSL. The company operates in a highly competitive and rapidly evolving industry, competing with large pharmaceutical and biopharmaceutical companies, as well as specialized biotechnology firms.

Recent Strategic Developments:

• Clinical Focus: In January 2026, CURIS, INC. announced a strategic focus on its ongoing combination Phase 1/2 study of emavusertib in relapsed/refractory (R/R) PCNSL with ibrutinib (TakeAim Lymphoma Phase 1/2 study) and its recently initiated Phase 2 combination study of emavusertib in chronic lymphocytic leukemia (CLL) with zanubrutinib (TakeAim CLL study). Monotherapy and combination studies of emavusertib in AML are substantially complete, with further development contingent on additional funding.
• Regulatory Progress (PCNSL): Productive meetings were held in March 2025 with the European Committee for Medicinal Products for Human Use (CHMP) and the FDA regarding a potential accelerated regulatory path for emavusertib in R/R PCNSL. Feedback indicated that the current single-arm study could support a Conditional Marketing Authorization (CMA) in Europe and an Accelerated Approval New Drug Application (NDA) in the U.S., with specific requirements for patient numbers, primary endpoints (Overall Response Rate, ORR), and contribution of effect analysis.
• Financing: In January 2026, CURIS, INC. completed a private placement (January 2026 PIPE Financing) for net proceeds of approximately $18.6 million.
• Asset Divestiture: In November 2025, CURIS, INC. sold its 100% interest in Curis Royalty LLC, including the Erivedge intellectual property and the Genentech License Agreement, to TPC Investments Royalty LLC for $2.5 million upfront consideration and a release of liability related to the sale of future royalties. This transaction means CURIS, INC. is no longer entitled to revenues under the Genentech License Agreement.

Geographic Footprint: CURIS, INC.'s operations are located entirely within the U.S., with its headquarters in Lexington, Massachusetts. Its collaboration with Aurigene Discovery Technologies Limited grants it exclusive licenses for development and commercialization worldwide, except for India and Russia. Regulatory approvals are being pursued in the U.S. and Europe.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 100% (Calculated as (Total Revenue - Cost of Royalties) / Total Revenue. Cost of royalties was $0.045 million in 2025 and $0.098 million in 2024, making gross profit effectively equal to total revenue for these periods.)
• Operating Margin: -60.5% (Calculated as Operating Income / Total Revenue)
• Net Margin: -80.5% (Calculated as Net Income / Total Revenue)

Investment in Growth:

• R&D Expenditure: $28.3 million (300% of revenue)
• Capital Expenditures: Not explicitly stated, but depreciation and amortization expense was $0.2 million for both 2025 and 2024.
• Strategic Investments: Not explicitly stated as separate line items beyond R&D.

Business Segment Analysis

CURIS, INC. operates in a single reportable segment, which is the research and development of innovative drug candidates for the treatment of human cancer.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported.
• Dividend Payments: CURIS, INC. has never declared nor paid cash dividends on its common stock and plans to retain all future earnings to finance business operations and growth.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None.

Balance Sheet Position:

• Cash and Equivalents: $5.1 million (as of December 31, 2025)
• Total Debt: Not explicitly stated as traditional debt, but the company had a "Liability related to the sale of future royalties" of $26.6 million as of December 31, 2024, which was extinguished in November 2025.
• Net Cash Position: -$9.4 million (Calculated as Cash and Cash Equivalents - Total Liabilities, excluding the extinguished royalty liability, as of December 31, 2025)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as traditional debt is not reported.

Cash Flow Generation:

• Operating Cash Flow: -$27.2 million (2025)
• Free Cash Flow: Not explicitly stated, but given the nature of operations and minimal capital expenditures, it would be close to operating cash flow.
• Cash Conversion Metrics: Not explicitly stated.

Operational Excellence

Production & Service Model: CURIS, INC. does not possess its own manufacturing capabilities. It relies on collaborators, subcontractors, and third-party manufacturers and suppliers for the production of its drug candidates. The manufacturing process for emavusertib is described as potentially complex, difficult to scale-up, and subject to delays, inefficiencies, and low yields.

Supply Chain Architecture: Key Suppliers & Partners:

• Raw Materials Suppliers: A small number of third-party suppliers provide certain raw materials for emavusertib production. Purchases are on a purchase order basis, without long-term supply agreements.
• Contract Manufacturing Organizations (CMOs): Third-party CMOs are used for drug substance and drug product production, packaging, labeling, and distribution under GMP controls. One CMO has a Chinese subcontractor for regulatory starting materials, and another CMO operates in Canada for drug product.
• Clinical Trial Services: Consultants, clinical investigators, contract research organizations (CROs), and other similar entities are heavily relied upon for preclinical testing, clinical trials, and related services.

Facility Network:

• Headquarters: Lexington, Massachusetts, consisting of approximately 21,772 square feet of office and laboratory space under a lease agreement expiring April 30, 2027.
• Manufacturing: Relies on third-party facilities.
• Research & Development: Conducted internally at headquarters and through third-party CROs.
• Distribution: Relies on third-party infrastructure.

Operational Metrics: No specific operational metrics such as capacity utilization or efficiency measures are explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels: CURIS, INC. currently has no sales, marketing, or distribution experience or infrastructure. If emavusertib receives regulatory approval, the company plans to rely primarily on sales, marketing, and distribution arrangements with third parties, including collaborative partners. Customer Portfolio:

• Enterprise Customers: Historically, Genentech, Inc. was a key customer through a collaboration for Erivedge, which generated royalty revenues. This relationship ended with the sale of Erivedge in November 2025.
• Strategic Partnerships: The primary strategic partnership is with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds, including emavusertib.
• Customer Concentration: Historically, Genentech, Inc. accounted for 100% of total gross revenues in 2025 and 2024. This concentration risk has been eliminated with the divestiture of Erivedge.

Geographic Revenue Distribution: Historically, revenues were derived from worldwide sales of Erivedge by Genentech, Inc. and Roche. Following the sale of Erivedge, no specific geographic revenue distribution is reported.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The human therapeutics industry, particularly in oncology, is characterized by intense and rapidly evolving competition. Success depends on differentiating products based on efficacy, safety, dosing, administration route, convenience, and cost-effectiveness. The underlying technologies are subject to rapid and significant advancement and unpredictable changes.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• IRAK4 Inhibitors: Kurome Therapeutics (KME-0584 – IRAK1/4 / FLT3), Rigel Pharmaceuticals, Inc. (R289), AstraZeneca (AZD2962), Hangzhou Polymed Biopharmaceuticals (HPB-092 – IRAK4 / FLT3), and Eilean Therapeutics (lomonitinib – IRAK4 / FLT3).
• Frontline CLL (BTK inhibitor combinations): AstraZeneca PLC (acalabrutinib with venetoclax), BeOne Medicines (zanubrutinib with venetoclax), AbbVie Inc. and Johnson & Johnson (ibrutinib with venetoclax). Other BTK inhibitor-based or next-generation BTK-pathway agents include Eli Lilly and Company (pirtobrutinib) and Nurix Therapeutics, Inc. (BTK degraders).
• PCNSL (BTK inhibitor combinations): Bayer AG (copanlisib with ibrutinib). Other companies pursuing PCNSL include Gilead Sciences, Inc. (axicabtagene ciloleucel), Ono Pharmaceuticals Co., Ltd. (tirabrutinib), and BeOne Medicines (zanubrutinib with rituximab and methotrexate). Marketed products like ibrutinib, rituximab, and lenalidomide are also being studied in combination.
• FLT3 Inhibitors: Astellas Pharma, Inc. (gilteritinib), Daiichi Sankyo (quizartinib), Jiangsu Hengrui (famitinib malate), Novartis (midostaurin). Other developers include Aptose Biosciences, Inc. (tuspetinib), HEC Pharma Co., Ltd. (HEC73543), Ellipses Pharma (EP0042), CSPC Pharmaceuticals Group Limited (SKLB1028), Kurome Therapeutics (KME-0584 – IRAK1/4 / FLT3), Hangzhou Polymed Biopharmaceuticals (HPB-092 – IRAK4 / FLT3), and Eilean Therapeutics (lomonitinib – IRAK4 / FLT3).
• Frontline AML (azacitidine and venetoclax combinations): Faron Pharmaceuticals Oy (bexmarilimab), Novartis AG (sabatolimab), OncoVerity, Inc. (cusatuzumab), Glycomimetics, Inc. (uproleselan), Shattuck Labs, Inc. (SL-17254), Bio-Path Holdings, Inc. (prexigebersen), Astellas Pharma, Inc. (gilteritinib), and AbbVie Inc. (pivekimab sunirine).

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions are constant threats in the rapidly advancing biotechnology and pharmaceutical industries.

Competitive Response Strategy: CURIS, INC.'s strategy involves developing proprietary positions in key scientific areas and efficiently evaluating product opportunities. The company relies on strategic collaborators for research, preclinical evaluation, clinical development, manufacturing, and marketing.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Drug Development Failure: Heavy dependence on emavusertib, which is in early clinical development. Clinical trials may not be successful, leading to delays or inability to commercialize.
• Market Acceptance: Even if approved, emavusertib may not achieve sufficient market acceptance by physicians, patients, and payors, impacting revenue generation.
• Resource Allocation: Limited resources may be expended on less profitable or less successful drug candidates or indications.
• Competition: Substantial competition from companies with greater resources and experience could lead to superior or earlier-to-market drugs.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Dependence: Reliance on third parties for manufacturing emavusertib introduces risks of delays, non-compliance with regulations (cGMP), and potential loss of proprietary information.
• Limited Raw Material Suppliers: Dependence on a small number of suppliers for critical raw materials exposes the company to risks of delays, shortages, interruptions, or contamination, which could disrupt manufacturing and clinical trials.
• Companion Drug Availability: Dependence on third parties for companion drugs (e.g., ibrutinib, zanubrutinib) for combination studies. Insufficient quantities could significantly delay development.
• Clinical Trial Execution: Reliance on third parties (CROs, investigators) to conduct clinical trials. Inadequate performance, failure to meet deadlines, or non-compliance with GCP could delay or prevent regulatory approvals.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Uncertainty: Recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern beyond 12 months from the 10-K filing date. Substantial additional capital is required.
• Funding Requirements: Will require substantial additional capital through equity financings, collaborations, or strategic transactions. Difficulties in raising capital could force delays, reductions, or elimination of development programs.
• Profitability: Has incurred substantial losses since inception and expects to continue doing so. May never generate significant revenue or achieve profitability.
• Stock Price Volatility: Stock price is highly volatile due to clinical trial results, regulatory actions, market conditions, and financing activities.
• Dilution: Future sales of common stock, including through "at-the-market" offerings, could result in dilution.
• Reimbursement and Pricing: Even if approved, emavusertib may face unfavorable pricing regulations, third-party payor reimbursement practices, or healthcare reform initiatives, harming commercial success.

Regulatory & Compliance Risks:

• Marketing Approval Uncertainty: Has never obtained marketing approval for a drug candidate. The approval process is expensive, time-consuming, and uncertain, potentially leading to delays or rejection.
• Post-Approval Regulation: Approved products are subject to ongoing stringent regulation, including manufacturing, safety reporting, and promotion. Non-compliance could lead to withdrawal from the market or penalties.
• Accelerated Approval Pathways: May seek accelerated approval pathways (Breakthrough Therapy, Fast Track, PRIME), but there is no guarantee of receiving such designations or that they will lead to faster development or approval. New FDA requirements for accelerated approval (e.g., confirmatory trials underway) add complexity.
• Companion Diagnostics: If required, delays or failure to obtain approval for a companion diagnostic would prevent commercialization of the therapeutic product.
• Generic Competition: If approved, small molecule products could face competition from generic versions, reducing sales.
• Healthcare Laws and Regulations: Subject to fraud and abuse, anti-kickback, false claims, and patient privacy laws (HIPAA, state laws, GDPR). Non-compliance could result in significant penalties and reputational harm.
• Data Privacy: Stringent and evolving privacy laws (GDPR, CCPA, CPRA, My Health My Data Act) and cybersecurity risks (breaches, cyber-attacks) could lead to fines, litigation, and disruption.
• Government Agency Disruptions: Funding cuts, personnel losses, regulatory reform, or government shutdowns (e.g., FDA RIF, PDUFA funding uncertainty) could delay guidance and approvals.

Geopolitical & External Risks

Geopolitical Exposure:

• Trade Policy Uncertainty: Changes in U.S. trade policy and international trade policies, particularly with China (e.g., tariffs, BIOSECURE Act), could impact supply chain, increase costs, and disrupt operations due to reliance on Chinese subcontractors. Recent Supreme Court ruling on IEEPA tariffs and new Section 122 tariffs create ongoing uncertainty.
• Environmental, Health, and Safety: Subject to laws governing hazardous materials. Non-compliance could lead to fines, penalties, or significant costs.
• Public Health Crises: Epidemics/pandemics could disrupt business activities, supply chains, and increase cybersecurity risks due to remote work.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• IRAK4 Inhibition: Emavusertib is a small molecule inhibitor of IRAK4, which plays a role in TLR and IL-1R signaling pathways, frequently dysregulated in cancer.
• FLT3 Inhibition: Emavusertib also inhibits FLT3.
• Immuno-oncology & Precision Oncology: Collaboration with Aurigene Discovery Technologies Limited focuses on these areas, with licensed programs including IRAK4, PD1/TIM3 (CA-327), and another immuno-oncology program. Innovation Pipeline:
• Emavusertib: Currently in Phase 1/2 for R/R PCNSL (in combination with ibrutinib) and Phase 2 for frontline CLL (in combination with zanubrutinib). AML studies are substantially complete, with further development contingent on funding.
• CA-327: A small molecule antagonist of PD1 and TIM3 immune checkpoint pathways, licensed under the Aurigene collaboration.

Intellectual Property Portfolio:

• Patent Strategy: Policy is to obtain and enforce patents and proprietary technology rights. Files U.S. and foreign patent applications for compositions of matter, methods of making and using, drug screening, and proprietary technologies.
• Patent Holdings: As of December 31, 2025, holds 52 issued or allowed U.S. patents expiring between 2028 and 2042, with foreign counterparts.
  • Emavusertib: 10 issued or allowed U.S. patents expiring between 2035 and 2042, licensed from Aurigene.
  • Other Aurigene Programs: 14 issued U.S. patents expiring between 2034 and 2038 for PD-L1/TIM3 and other immuno-oncology compounds.
• Licensing Programs: Has exclusive licenses from Aurigene for emavusertib and other programs (worldwide, except India and Russia).
• IP Litigation: No material IP litigation is currently pending, but the company acknowledges the risk of expensive and unpredictable patent litigation.

Technology Partnerships:

• Strategic Alliances: Exclusive collaboration with Aurigene Discovery Technologies Limited for discovery, development, and commercialization of small molecule compounds in immuno-oncology and precision oncology.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company depends on its senior management team, and the loss of key members could significantly delay or prevent business objectives. Succession planning and leadership development initiatives are not explicitly detailed.

Board Composition: The board of directors is divided into three classes serving staggered three-year terms. Specific details on independence, expertise areas, or committee structure are incorporated by reference to the 2026 proxy statement.

Human Capital Strategy

Workforce Composition:

• Total Employees: 24 employees as of February 9, 2026.
• Geographic Distribution: Not explicitly detailed beyond "entirely within the U.S."
• Skill Mix: 14 employees are involved in research and development, including medical doctors, biologists, and other clinical or scientific disciplines.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Aims to attract and retain highly skilled managerial, scientific, and medical personnel in a competitive industry.
• Retention Metrics: Not explicitly stated.
• Employee Value Proposition: Offers a comprehensive compensation package including salaries, annual bonuses, equity compensation, 401(k) match, life insurance, health and workers’ compensation insurance, paid vacation, holidays, and year-end shutdown. Equity compensation plans are designed to align employee interests with stockholders.

Diversity & Development:

• Diversity Metrics: Not explicitly stated.
• Development Programs: Not explicitly detailed beyond general talent management.
• Culture & Engagement: Not explicitly detailed.

Environmental & Social Impact

Environmental Commitments: Not explicitly detailed in the filing.

Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives: Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: Not explicitly detailed in the filing. The company's focus on drug development means its revenue is not yet subject to typical demand patterns for commercialized products.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: Subject to extensive regulation by the FDA in the U.S. and comparable foreign regulatory authorities (e.g., EMA in the EU) covering research, development, testing, manufacturing, quality control, approval, labeling, advertising, promotion, distribution, marketing, sales, pricing, reimbursement, and post-approval monitoring.
• International Compliance: Must comply with varying regulatory requirements in foreign countries, including the EU's Clinical Trials Regulation (CTR) and the UK's regulatory regime (MHRA, ILAP, IRP).
• Recent Regulatory Changes: The FDA's Modernization Act 2.0 (eliminating animal testing requirement), updated GCP guidance, patient-focused drug development guidance, and diversity action plan (DAP) requirements (FDORA) are noted. The EU's new Pharma Package (expected mid-2026) may reduce regulatory exclusivity periods.

Trade & Export Controls:

• Export Restrictions: Subject to U.S. export control and import laws (Export Administration Regulations, Customs regulations, OFAC sanctions).
• Sanctions Compliance: Must comply with economic and trade sanctions regulations.

Legal Proceedings: CURIS, INC. is not currently a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% for 2025 and 2024 due to continued operating losses and a full valuation allowance against deferred tax assets.
• Geographic Tax Planning: International tax structure and transfer pricing are not explicitly detailed.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), passed July 4, 2025, permanently suspends the requirement to capitalize and amortize domestic R&D expenditures for tax years beginning after December 31, 2024. CURIS, INC. plans to currently expense domestic R&D costs starting in 2025 and amortize previously capitalized domestic R&D expenses over their remaining lives. Foreign R&D costs will continue to be capitalized over fifteen years.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, had U.S. federal tax-effected NOL carryforwards of $99.1 million ($30.1 million expiring 2026-2037, remainder indefinite but subject to 80% limitation) and state NOL carryforwards of $24.6 million (expiring 2033-2044).
• Tax Credit Carryforwards: As of December 31, 2025, had federal R&D credit carryforwards of $14.1 million (expiring 2026-2044), state R&D credit carryforwards of $4.3 million (expiring 2026-2039), and orphan drug tax credit carryforwards of $29.4 million (expiring 2035-2044).
• Valuation Allowance: A full valuation allowance of $211.8 million was recorded as of December 31, 2025, indicating that the company does not expect to realize the benefits of its deferred tax assets.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains product liability insurance for clinical trials, subject to deductibles and limitations. Does not maintain insurance for environmental liability or toxic tort claims.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.